PLRZ
Polyrizon Ltd.
NASDAQ · Healthcare · Biotechnology · IL
$11.24
−10.51%Sep 3, 2026, 12:50 UTC
Polyrizon Ltd. entered into definitive agreements with a single institutional investor for a registered direct offering of ordinary shares and pre-funded warrants, plus a concurrent private placement of pre-funded and investor warrants, expecting aggregate gross proceeds of approximately $4.0 million.
Aug 20, 2026, 13:30 UTC
Polyrizon completed contracting with all five U.S. clinical sites for its NASARIX™ Allergy Blocker (PL-14) study and is advancing toward enrollment of 120 patients.
Jul 2, 2026, 11:32 UTC
Polyrizon Ltd. announced successful results from its biocompatibility evaluation program for its NASARIX Allergy Blocker nasal spray, supporting advancement towards a first in human clinical trial.
Source:Jun 29, 2026, 12:44 UTC
Polyrizon Ltd. received central IRB approval to begin its first human clinical trial for NASARIX™, its innovative nasal spray designed to block airborne allergens.
Source:Jun 8, 2026, 13:25 UTC
Polyrizon Ltd. signed agreements with two additional U.S. clinical sites for its NASARIX clinical study.
Source:Jun 5, 2026, 20:23 UTC
Polyrizon Ltd. extended the exclusivity period and initial negotiation phase for its proposed acquisition of a 51% stake in Arrow Aviation Ltd. to June 30, 2026.
Source: